Orally disintegrating tablets market driven by CNS disease treatments
The preference for orally disintegrating tablets (ODT) to treat CNS-related diseases will increase the market from $12bn in 2018, with a solid growth rate.
List view / Grid view
The preference for orally disintegrating tablets (ODT) to treat CNS-related diseases will increase the market from $12bn in 2018, with a solid growth rate.
The global biobetters market is set to increase due to demand for higher efficacy and safer drugs.